載入...
Immunotherapy for Type 1 Diabetes – targeting the innate immune system
Moran et al report two trials of antagonism of the pro-inflammatory cytokine, IL-1, assessing the monoclonal antibody canakinumab and the IL-1 antagonist, anakinra in new-onset Type 1 Diabetes (T1D). The studies both showed that, although relatively safe, there was no efficacy in terms of halting de...
Na minha lista:
| Main Authors: | , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2013
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4048745/ https://ncbi.nlm.nih.gov/pubmed/23732280 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrendo.2013.103 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|